Positions

Overview

  • Pi-Ling Chang, PhD is an Associate Professor of Nutrition Sciences at the University of Alabama at Birmingham (UAB). Dr. Chang received her baccalaureate degree in Natural Sciences and Master’s degree in Biochemistry from the University of Chicago. After serving as an instructor in the Department of Biochemistry at the King Saud University, Scientific College for Girls in Saudi Arabia for 5 years, she returned to the United States and earned her doctorate degree in Nutrition Sciences under the mentorship of Dr. Charles Prince at UAB. Dr. Chang’s major research interest focuses on understand how a normal cell develops into a tumor cells in the context of alteration in the cellular microenvironment triggered by external stresses. Specifically, how an elevation of a matricellular protein promote or facilitate a normal cells exposed to carcinogens, tumor promoters or ultraviolet radiation) transform into benign and subsequently, malignant tumors. More recently, Dr. Chang is also investigating novel rexinoids, RXR agonists, in collaboration with UAB chemists and physicians, for the potential treatment of cutaneous T-cell lymphomas, a rare disease with increasing incidence. Besides on-going research, Dr. Chang is teaching several courses in the department of Nutrition Sciences.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axisJournal of Dermatological Science.  90:343-356. 2018
    2015 Osteopontin mediates tumorigenic transformation of a preneoplastic murine cell line by suppressing anoikis: An Arg-Gly-Asp-dependent-focal adhesion kinase-caspase-8 axisMolecular Carcinogenesis.  54:379-392. 2015
    2014 Osteopontin facilitates ultraviolet B-induced squamous cell carcinoma developmentJournal of Dermatological Science.  75:121-132. 2014
    2012 Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cellsInternational Journal of Cancer.  131:322-333. 2012
    2011 Reduced mitogenicity of sera following weight loss in premenopausal womenNutrition and Cancer.  63:916-923. 2011
    2010 Establishment and characterization of an osteopontin-null cutaneous squamous cell carcinoma cell lineIn Vitro Cellular and Developmental Biology - Animal.  46:87-91. 2010
    2008 Osteopontin expression in normal skin and non-melanoma skin tumorsJournal of Histochemistry and Cytochemistry.  56:57-66. 2008
    2006 Papilloma development is delayed in osteopontin-null mice: Implicating an antiapoptosis role for osteopontinCurrent Protocols in Toxicology.  66:7119-7127. 2006
    2006 Comparison of fetal and adult marrow stromal cells in osteogenesis with and without glucocorticoidsCancer Ther Oncol Int J.  47:67-76. 2006
    2006 Production of chemokine CXCL1/KC by okadaic acid through the nuclear factor-κB pathwayJournal of Autoimmunity.  27:43-52. 2006
    2005 Erratum: Primary human marrow stromal cells and Saos-2 osteosarcoma cells use different mechanisms to adhere to hydroxylapatite (Journal of Biomedical Materials Research - Part A (2004) 68A, 2 (273-285) DOI: 10.1002/jbm.a.20043)Journal of Biomedical Materials Research.  73:254. 2005
    2004 Primary human marrow stromal cells and Saos-2 osteosarcoma cells use different mechanisms to adhere to hydroxylapatiteJournal of Biomedical Materials Research.  68:273-285. 2004
    2003 Differential expression of mammalian or viral promoter-driven gene in adherent versus suspension cellsIn Vitro Cellular and Developmental Biology - Animal.  39:420-423. 2003
    2003 Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cellsJournal of Autoimmunity.  24:1749-1758. 2003
    2002 Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: Differences in integrin signaling during cell adhesion to osteopontin versus vitronectinCurrent Protocols in Toxicology.  62:5336-5343. 2002
    2002 Novel protein kinase C isoforms and mitogen-activated kinase kinase mediate phorbol ester-induced osteopontin expressionThe International journal of biochemistry.  34:1142-1151. 2002
    2001 Hydroxylapatite binds more serum proteins, purified integrins, and osteoblast precursor cells than titanium or steelJournal of Biomedical Materials Research.  57:258-267. 2001
    2001 Omega-3 fatty acids decrease protein kinase expression in human breast cancer cellsActa Physica Polonica B.  67:279-283. 2001
    2000 Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: Effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblastsCancer Genetics and Cytogenetics.  43:1597-1605. 2000
    2000 Attachment of primary neonatal rat astrocytes to vitronectin is mediated by integrins αvβ5 and α8β1: Modulation by the type 1 plasminogen activator inhibitorNeuroscience Letters.  283:157-161. 2000
    2000 Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontinJournal of Cellular Biochemistry.  78:8-23. 2000
    1998 Osteopontin stimulates a subpopulation of quiescent human prostate epithelial cells with high proliferative potential to divide in vitroProstate.  35:83-94. 1998
    1998 TPA-mediated regulation of osteopontin in human malignant glioma cellsAnnals of the Rheumatic Diseases.  18:807-812. 1998
    1998 TPA-mediated regulation of osteopontin in human malignant glioma cells.Annals of the Rheumatic Diseases.  18:807-812. 1998
    1998 Cyclic GMP-dependent protein kinase inhibits osteopontin and thrombospondin production in rat aortic smooth muscle cellsBiologie Aujourd'hui.  82:139-146. 1998
    1997 Phosphorylation of osteopontin by Golgi apparatus casein kinaseJournal of Healthcare Leadership.  240:602-605. 1997
    1997 Calcitriol enhancement of TPA-induced tumorigenic transformation is mediated through vitamin D receptor-dependent and -independent pathwaysACM Computing Surveys.  15:580-592. 1997
    1997 Human osteosarcoma MG-63 cells plus or minus calcitriol treatment do not secrete osteopontinFederation proceedings.  11:3199-3199. 1997
    1996 Effects of calcitriol and its analogs on osteopontin expression in rat osteosarcoma (ROS 17/2.8) and mouse osteoblast (MC3T3-E1) cellsFederation proceedings.  10. 1996
    1996 Isolation of phosphorated and non-phosphorylated osteopontin by immobilized metal (Fe+ ) affinity chromatographyFederation proceedings.  10. 1996
    1996 Osteopontin stimulates proliferation of a population of progenitors of prostate epithelial cells.International Journal of Athletic Therapy and Training.  7:1421-1421. 1996
    1995 Effects of Okadaic Acid on Calcitriol‐and Phorbol Ester‐Induced Expression and Phosphorylation of Osteopontin in Mouse JB6 Epidermal CellsOnkologie.  760:24-34. 1995
    1994 Calcitriol regulation of osteopontin expression in mouse epidermal cellsJournal of Physician Assistant Education.  135:863-869. 1994
    1993 1-ALPHA,25-DIHYDROXYVITAMIN-D(3) ENHANCES 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED TUMORIGENIC TRANSFORMATION AND OSTEOPONTIN EXPRESSION IN MOUSE JB6 EPIDERMAL-CELLSCurrent Protocols in Toxicology.  53:2217-2220. 1993
    1993 Calcium-binding properties of osteopontin derived from non-osteogenic sourcesJournal of Biochemistry.  114:702-707. 1993
    1993 la,25-Dihydroxyvitamin D3 Enhances 12-0-Tetradecanoylphorbol-13-acetate-induced Tumorigenic Transformation and Osteopontin Expression in Mouse JB6 Epidermal Cells1Current Protocols in Toxicology.  53:2217-2220. 1993
    1991 1α,25-Dihydroxyvitamin D3 Stimulates Synthesis and Secretion of Nonphosphorylated Osteopontin (Secreted Phosphoprotein 1) in Mouse JB6 Epidermal CellsCurrent Protocols in Toxicology.  51:2144-2150. 1991
    1991 INDUCTION OF NONPHOSPHORYLATED OSTEOPONTIN IN MOUSE JB6 EPIDERMAL-CELLS BY CALCITRIOL IS NOT ASSOCIATED WITH TRANSFORMATIONFederation proceedings.  5:A1643-A1643. 1991

    Research Overview

  • Project 1. Determining the function and regulation of matricellular protein, osteopontin, in normal and pathological conditions.
    Project 2. Assessing the therapeutic efficacy of novel RXR agonists for the treatment of cutaneous T-cell lymphoma (CTCL)
  • Teaching Overview

  • Dr. Chang has more than 20 years of teaching experience through mentoring graduate students in research laboratory, in class, and on-line. She was awarded the Dean's Excellence in Mentorship Award in 2017. She is presently serving as the course director for 3 courses: NTR 747 Molecular Biology and Nutrition Sciences, NTR 637 Applied Research in Nutrition Sciences, and NTR 690 Seminar.
  • Education And Training

  • Doctor of Philosophy in Nutrition Sciences, University of Alabama at Birmingham 1992
  • Bachelor of Arts in Natural Sciences, University of Chicago 1981
  • Master of Life Sciences in Biochemistry, University of Chicago 1981
  • Full Name

  • Pi-Ling Chang